Molecularly targeted treatment for dermatofibrosarcoma protuberans.

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive skin tumor.
• Standard treatment involves wide surgical excision, but recurrence is common.
• DFSP pathogenesis involves a chromosomal rearrangement leading to deregulated platelet-derived growth factor (PDGF) signaling.

Purpose of the Study:

• To evaluate the efficacy of imatinib in treating dermatofibrosarcoma protuberans.
• To explore imatinib as an alternative therapeutic option for unresectable or partially resectable DFSP.
• To investigate the role of PDGFB and PDGFRbeta in DFSP growth.

Main Methods:

• Review of preclinical investigations and clinical reports on imatinib in DFSP.
• Analysis of imatinib's mechanism of action as a protein-tyrosine kinase inhibitor.
• Assessment of imatinib's potential to target the PDGFRbeta pathway in DFSP.

Main Results:

• Imatinib is a potent and specific inhibitor of platelet-derived growth factor receptors (PDGFRs).
• Preclinical and clinical data indicate imatinib's efficacy in DFSP treatment.
• Imatinib demonstrates potential in managing unresectable or partially resectable DFSP cases.

Conclusions:

• Imatinib offers a promising therapeutic alternative for dermatofibrosarcoma protuberans.
• Targeting the PDGFB/PDGFRbeta pathway with imatinib may improve DFSP treatment outcomes.
• Imatinib could enhance the effectiveness of surgical interventions for DFSP.